Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial

Alzheimer's and Dementia

Volumn 12, Issue 12, 2016, Pages 1216-1225

  Coley, Nicola ^a,b   Gallini, Adeline ^a,b   Ousset, Pierre Jean ^a,b   Vellas, Bruno ^a,b   Andrieu, Sandrine ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical relevance; Clinical trials; Cognition; Cognitive composite score; Dementia; Outcome measures; Power; Preclinical Alzheimer's disease; Prevention

Indexed keywords

APOLIPOPROTEIN E; GINKGO BILOBA EXTRACT;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL OUTCOME; COGNITION; DISEASE COURSE; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENOTYPE; GERIATRIC DEPRESSION SCALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; ORIENTATION; PRIORITY JOURNAL; RECALL; RETROSPECTIVE STUDY; SECONDARY ANALYSIS; TRAIL MAKING TEST; EVALUATION STUDY; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

AGED; ALZHEIMER DISEASE; COGNITION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84996743380     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.06.002     Document Type: Article

References (47)

1. [1] Andrieu, S., Coley, N., Lovestone, S., Aisen, P.S., Vellas, B., Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol 14 (2015), 926–944.
2. [2] Sperling, R.A., Jack, C.R. Jr., Aisen, P.S., Testing the right target and right drug at the right stage. Sci Transl Med, 3, 2011, 111cm33.
3. [3] Vellas, B., Andrieu, S., Sampaio, C., Coley, N., Wilcock, G., Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 7 (2008), 436–450.
4. [4] Cedarbaum, J.M., Jaros, M., Hernandez, C., Coley, N., Andrieu, S., Grundman, M., et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimers Dement 9:1 Suppl (2013), S45–S55.
5. [5] Coley, N., Andrieu, S., Jaros, M., Weiner, M., Cedarbaum, J., Vellas, B., Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimers Dement 7 (2011), 602–610.e2.
6. [6] Jack, C.R. Jr, Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
7. [7] Hampel, H., Wilcock, G., Andrieu, S., Aisen, P., Blennow, K., Broich, K., et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 95 (2011), 579–593.
8. [8] Khan, T.K., Alkon, D.L., Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. J Alzheimers Dis 46 (2015), 817–836.
9. [9] Jack, C.R. Jr, Barkhof, F., Bernstein, M.A., Cantillon, M., Cole, P.E., Decarli, C., et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 7 (2011), 474–485.e4.
10. [10] Amieva, H., Le Goff, M. Millet, X., Orgogozo, J.M., Pérès, K., Barberger-Gateau, P., et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 64 (2008), 492–498.
11. [11] Birks, J.S., Grimley Evans, J., Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev, 4, 2015, CD001191.
12. [12] Proust-Lima, C., Amieva, H., Dartigues, J.F., Jacqmin-Gadda, H., Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol 165 (2007), 344–350.
13. [13] Langbaum, J.B., Hendrix, S.B., Ayutyanont, N., Chen, K., Fleisher, A.S., Shah, R.C., et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement 10 (2014), 666–674.
14. [14] Burnham, S.C., Raghavan, N., Wilson, W., Baker, D., Ropacki, M.T., Novak, G., et al. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. J Alzheimers Dis 46 (2015), 1079–1089.
15. [15] European Medicines Agency. Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. EMA/CHMP/539931, 2014, European Medicines Agency, London.
16. [16] Donohue, M.C., Sperling, R.A., Salmon, D.P., Rentz, D.M., Raman, R., Thomas, R.G., et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71 (2014), 961–970.
17. [17] Vellas, B., Coley, N., Ousset, P.J., Berrut, G., Dartigues, J.F., Dubois, B., et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11 (2012), 851–859.
18. [18] Andrieu, S., Ousset, P.J., Coley, N., Ouzid, M., Mathiex-Fortunet, H., Vellas, B., GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Curr Alzheimer Res 5 (2008), 406–415.
19. [19] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., 1994, American Psychiatric Association, Washington, DC.
20. [20] McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
21. [21] Grober, E., Buschke, H., Crystal, H., Bang, S., Dresner, R., Screening for dementia by memory testing. Neurology 38 (1988), 900–903.
22. [22] Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
23. [23] Hughes, C.P., Berg, L., Danziger, W.L., Coben, L.A., Martin, R.L., A new clinical scale for the staging of dementia. Br J Psychiatry 140 (1982), 566–572.
24. [24] Lipman, T., Covi, L., Outpatient treatment of neurotic depression: medication and group psychotherapy. Spitzer, R., Klein, D., (eds.) Evaluation of Psychological Therapies, 1976, Johns Hopkins University Press, Baltimore MD, 181–202.
25. [25] Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17 (1982), 37–49.
26. [26] Reitan, R., Validity of the Trail Making Test as an indicator of brain damage. Percept Mot Skills 8 (1958), 271–276.
27. [27] Cardebat, D., Doyon, B., Puel, M., Goulet, P., Joanette, Y., Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 90 (1990), 207–217 [In French].
28. [28] Lawton, M.P., Brody, E.M., Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9 (1969), 179–186.
29. [29] Smelt, A.F., Assendelft, W.J., Terwee, C.B., Ferrari, M.D., Blom, J.W., What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia 34 (2014), 29–36.
30. [30] Youden, W.J., Index for rating diagnostic tests. Cancer 3 (1950), 32–35.
31. [31] Anderson-Hanley, C., Arciero, P.J., Brickman, A.M., Nimon, J.P., Okuma, N., Westen, S.C., et al. Exergaming and older adult cognition: a cluster randomized clinical trial. Am J Prev Med 42 (2012), 109–119.
32. [32] Barnes, D.E., Santos-Modesitt, W., Poelke, G., Kramer, A.F., Castro, C., Middleton, L.E., et al. The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults. JAMA Intern Med 173 (2013), 797–804.
33. [33] Durga, J., van Boxtel, M.P., Schouten, E.G. Kok, F.J., Jolles, J., Katan, M.B., et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369 (2007), 208–216.
34. [34] Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized controlled trial. Lancet 385 (2015), 2255–2263.
35. [35] Kryscio, R.J., Abner, E.L., Schmitt, F.A., Goodman, P.J., Mendiondo, M., Caban-Holt, A., et al. A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. J Nutr Health Aging 17 (2013), 72–75.
36. [36] Meinert, C.L., Breitner, J.C., Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 4:1 Suppl 1 (2008), S7–S14.
37. [37] Dangour, A.D., Allen, E., Richards, M., Whitehouse, P., Uauy, R., Design considerations in long-term intervention studies for the prevention of cognitive decline or dementia. Nutr Rev 68 Suppl 1 (2010), S16–S21.
38. [38] Ferris, S.H., Aisen, P.S., Cummings, J., Galasko, D., Salmon, D.P., Schneider, L., et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord 20:4 Suppl 3 (2006), S109–S123.
39. [39] Mathews, M., Abner, E., Caban-Holt, A., Kryscio, R., Schmitt, F., CERAD practice effects and attrition bias in a dementia prevention trial. Int Psychogeriatr 25 (2013), 1115–1123.
40. [40] Vivot, A., Power, M.C., Glymour, M.M., Mayeda, E.R., Benitez, A., Spiro, A. 3rd, et al. Jump, hop, or skip: Modeling Practice Effects in Studies of Determinants of Cognitive Change in Older Adults. Am J Epidemiol 183 (2016), 302–314.
41. [41] Schrag, A., Schott, J.M., What is the clinically relevant change on the ADAS-Cog?. J Neurol Neurosurg Psychiatry 83 (2012), 171–173.
42. [42] Rockwood, K., Fay, S., Gorman, M., Carver, D., Graham, J.E., The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol, 7, 2007, 26.
43. [43] Vellas, B., Andrieu, S., Cantet, C., Dartigues, J.F., Gauthier, S., Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?. J Nutr Health Aging 11 (2007), 338–341.
44. [44] Yost, K.J., Eton, D.T., Garcia, S.F., Cella, D., Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol 64 (2011), 507–516.
45. [45] Yost, K.J., Cella, D., Chawla, A., Holmgren, E., Eton, D.T., Ayanian, J.Z., et al. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol 58 (2005), 1241–1251.
46. [46] Hsieh, Y.W., Wang, C.H., Sheu, C.F., Hsueh, I.P., Hsieh, C.L., Estimating the minimal clinically important difference of the Stroke Rehabilitation Assessment of Movement measure. Neurorehabil Neural Repair 22 (2008), 723–727.
47. [47] Vellas, B., Carrie, I., Gillette-Guyonnet, S., Touchon, J., Dantoine, T., Dartigues, J.F., et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. J Prev Alzheimers Dis 1 (2014), 13–22.